Document Detail


Moexipril versus captopril in patients with mild to moderate hypertension.
MedLine Citation:
PMID:  8961074     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Moexipril is a new, long-acting angiotensin-converting enzyme (ACE) inhibitor. In contrast to captopril, it is a prodrug of the pharmacologically active agent moexiprilat and will be administered once daily. The objective of this study was to compare the efficacy, safety, and tolerability of moexipril with that of captopril during a 12-week treatment of patients with mild to moderate hypertension. Patients with a sitting diastolic blood pressure (SDBP) of 95-114 mm Hg, inclusive, were randomized in a 2:1 ratio to receive moexipril, 7.5 mg, once daily or captopril, 25 mg, twice daily. After 6 weeks of treatment, the dose of moexipril and captopril was increased to 15 mg once daily and 50 mg twice daily, respectively, if the patient's SDBP remained > or = 90 mm Hg. Blood pressure was measured at biweekly visits. At study endpoint, adjusted mean reductions in SDBP were comparable between the moexipril and captopril groups (-9.8 vs. -8.7 mm Hg), and moexipril was more effective than captopril in reducing sitting systolic blood pressure. Adverse experiences (headache, dizziness, and upper respiratory infection) occurred at similar frequencies in the moexipril and in the captopril groups. The data indicate that moexipril at dosages of 7.5 and 15 mg once daily is as efficacious as twice daily captopril in reducing blood pressure in patients with mild to moderate hypertension.
Authors:
M Stimpel; B Koch; T Jansen; A Fox; I Loh
Related Documents :
215374 - Long-term treatment of hypertension in man by an orally active angiotensin-converting e...
3322604 - Bradykinin does not contribute to hypotension in early canine endotoxemia.
10981174 - Vasopeptidase inhibition: a new direction in cardiovascular treatment.
7601014 - Spirapril. a preliminary review of its pharmacology and therapeutic efficacy in the tre...
7361904 - Aerobic limit of the heart perfused at constant pressure.
1336154 - A hypothesis regarding possible interactions between the pressure-induced disorders in ...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  28     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1996 Dec 
Date Detail:
Created Date:  1997-04-09     Completed Date:  1997-04-09     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  769-73     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  therapeutic use*
Captopril / adverse effects,  therapeutic use*
Dizziness / chemically induced
Double-Blind Method
Fatigue / chemically induced
Female
Headache / chemically induced
Humans
Hypertension / drug therapy*
Isoquinolines / adverse effects,  therapeutic use*
Male
Middle Aged
Prodrugs / adverse effects,  therapeutic use*
Tetrahydroisoquinolines*
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Isoquinolines; 0/Prodrugs; 0/Tetrahydroisoquinolines; 9G64RSX1XD/Captopril; WT87C52TJZ/moexipril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Contractile effects of neuropeptide Y in human subcutaneous resistance arteries are mediated by Y1 r...
Next Document:  Role of endothelin in a rabbit model of acute myocardial infarction: effects of receptor antagonists...